ATH Receives A$3.98m R&D Tax Incentive
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
- FDA Meeting Minutes Confirm Registrational Path for ATH434
- Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Later from Alterity Therapeutics
- Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
- Application for quotation of securities - ATH
- Upcoming Expiry of ATHO Listed Options
- Quarterly Activities/Appendix 4C Cash Flow Report
- Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics